

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTABEM1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * Welcome to STN International * * * * * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 AUG 15 CAOLD to be discontinued on December 31, 2008
NEWS 3 OCT 07 EPFULL enhanced with full implementation of EPC2000
NEWS 4 OCT 07 Multiple databases enhanced for more flexible patent number searching
NEWS 5 OCT 22 Current-awareness alert (SDI) setup and editing enhanced
NEWS 6 OCT 22 WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT Applications
NEWS 7 OCT 24 CHEMLIST enhanced with intermediate list of pre-registered REACH substances
NEWS 8 NOV 21 CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS 9 NOV 26 MARPAT enhanced with FSORT command
NEWS 10 NOV 26 MEDLINE year-end processing temporarily halts availability of new fully-indexed citations
NEWS 11 NOV 26 CHEMSAFE now available on STN Easy
NEWS 12 NOV 26 Two new SET commands increase convenience of STN searching
NEWS 13 DEC 01 ChemPort single article sales feature unavailable
NEWS 14 DEC 12 GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS 15 DEC 17 Fifty-one pharmaceutical ingredients added to PS

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * STN Columbus * * * * * * * * *

FILE 'HOME' ENTERED AT 13:27:17 ON 24 DEC 2008

=> fil reg

COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE ENTRY 0.21
TOTAL SESSION 0.21

FILE 'REGISTRY' ENTERED AT 13:27:28 ON 24 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 23 DEC 2008 HIGHEST RN 1089286-03-2
DICTIONARY FILE UPDATES: 23 DEC 2008 HIGHEST RN 1089286-03-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\STNEXP\Queries\10590542.str




chain nodes :
7 8 16 20 21 22
ring nodes :
1 2 3 4 5 6 10 11 12 13 14 15
chain bonds :
3-7 7-8 8-20 13-16 20-21 20-22
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15
exact/norm bonds :
7-8 8-20 13-16 20-21
exact bonds :
3-7 20-22
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15
isolated ring systems :
containing 1 : 10 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:Atom 20:CLASS 21:CLASS 22:Atom
Generic attributes :
22:
Saturation : Saturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

L1 STRUCTURE UPLOADED

=> d 11
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11
SAMPLE SEARCH INITIATED 13:27:49 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 14552 TO ITERATE

13.7% PROCESSED 2000 ITERATIONS 1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 283813 TO 298267
PROJECTED ANSWERS: 1 TO 306

L2 1 SEA SSS SAM L1

=> s 11 sss full
FULL SEARCH INITIATED 13:27:55 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 291038 TO ITERATE

100.0% PROCESSED 291038 ITERATIONS
SEARCH TIME: 00.00.15


176 ANSWERS

L3 176 SEA SSS FUL L1

=> d scan

L3 176 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1H-Imidazole-5-carboxamide, N-[1-[[[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-1-methyl-
MF C24 H24 Cl12 F N5 O3

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 176 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Pyrazinecarboxamide, 6-chloro-N-[1-[[[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-
MF C24 H19 Cl13 F3 N5 O3

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 176 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Cyclopropanecarboxamide, N-[{(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl}-1-[(2,2,2-trifluoroacetyl)amino]-
 MF C21 H19 Cl12 F4 N3 O3

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 176 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 5-Thiazolecarboxamide, N-[1-[[[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-
 MF C23 H19 Cl12 F3 N4 O3 S

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 176 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Cyclopropanecarboxamide, 1-(acetylamino)-N-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]-
 MF C21 H20 Cl12 F3 N3 O3


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 176 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Cyclopropanecarboxamide, 1-(1,3-benzodioxol-5-yl)-N-[5-(2-methoxyphenyl)-4-methyl-2-pyridinyl]-
 MF C24 H22 N2 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 176 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 1,2,3-Thiadiazole-4-carboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-
 MF C22 H20 Cl12 F N5 O3 S

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 176 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 5-Isoxazolecarboxamide, N-[1-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-3-methoxy-
 MF C24 H21 Cl12 F3 N4 O5


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 176 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Cyclopropanecarboxamide, 1-(1,3-benzodioxol-5-yl)-N-[5-(2,6-dimethoxyphenyl)-2-pyridinyl]-
 MF C24 H22 N2 O5




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 176 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Cyclopropanecarboxamide, 1-(acetylamino)-N-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]-
 MF C21 H22 Cl2 F N3 O3

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 176 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 5-Isoxazolecarboxamide, N-[1-[[[(1R)-1-[3-chloro-5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-
 MF C23 H19 Cl13 F2 N4 O4


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 176 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN Cyclopropanecarboxamide, 1-(1,3-benzodioxol-5-yl)-N-[6-(5-fluoro-2-methoxyphenyl)-2-pyridinyl]-
 MF C23 H19 F N2 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 176 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 2-Pyrazinecarboxamide, N-[1-[[[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-
 MF C24 H22 Cl2 F N5 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil cap	COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
		178.82	179.03
FULL ESTIMATED COST			

FILE 'CAPLUS' ENTERED AT 13:28:47 ON 24 DEC 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Dec 2008 VOL 149 ISS 26
FILE LAST UPDATED: 23 Dec 2008 (20081223/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> d his

(FILE 'HOME' ENTERED AT 13:27:17 ON 24 DEC 2008)

FILE 'REGISTRY' ENTERED AT 13:27:28 ON 24 DEC 2008

L1 STRUCTURE UPLOADED
L2 1 S L1
L3 176 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 13:28:47 ON 24 DEC 2008

=> s 13
L4 12 L3

=> s 13 and (pry<2005)
 12 L3
 4595104 PRY<2005
L5 7 L3 AND (PRY<2005)

=> d 1-7 ibib abs hitstr


L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:1174539 CAPLUS
DOCUMENT NUMBER: 149:402214
TITLE: Preparation of pyridine carboxamides as serine
 protease inhibitors for treating thromboembolic and
 inflammatory disorders
INVENTOR(S): Corte, James R.; Hangeland, Jon J.; Quan, Mimi L.;
 Smallheer, Joanne M.; Fang, Tianan
PATENT ASSIGNEE(S): Bristol Myers Squibb Company, USA
SOURCE: U.S., 172pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 7429604	B2	20080930	US 2005-151627	20050613 <--

US 20060009455	A1	20060112		
AU 2005255029	A1	20051229	AU 2005-255029	20050614 <--
WO 2005123680	A1	20051229	WO 2005-US20971	20050614 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1773775	A1	20070418	EP 2005-787697	20050614 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV, MK, YU				
CN 101010299	A	20070801	CN 2005-80027485	20050614 <--
JP 2008502692	T	20080131	JP 2007-516646	20050614 <--
MX 2006PA14799	A	20070216	MX 2006-PA14799	20061215 <--
NO 2007000201	A	20070312	NO 2007-201	20070111 <--
KR 2007022867	A	20070227	KR 2007-700830	20070112 <--
PRIORITY APPLN. INFO.:				
US 2004-579637P P 20040615 <--				
US 2005-683838P P 20050524				
US 2005-151627 A 20050613				
WO 2005-US20971 W 20050614				

OTHER SOURCE(S): MARPAT 149:402214

GI



AB Title compds. [I; A = (substituted) cycloalkyl, cycloalkenyl, Ph, naphthyl, heterocyclyl; X1-X4 = CR₃, CR₄, NR₆, NO, CO; ≥1 of X1-X4 = CR₃; X5 = N, NR₆, NO; Z = CHR₁₁, NR₁₃; L = CONR₁₀, CH₂CONR₁₀, CH₂NR₁₀CO, etc.; R₃ = (CH₂)_rCONR₈R₉, Q(CH₂)_r, etc.; r = 0-4; Q = (substituted) Ph, heterocyclyl; R₄ = H, O, F, Cl, Br, iodo, OCF₃, CF₃, cyano, NO₂, CONR₈R₉, etc.; R₆ = H, alkyl, haloalkyl, (substituted) Ph(CH₂)_r, etc.; R₈ = H, (substituted) alkyl, Q(CH₂)_n; n = 0-4; R₉ = H, (substituted) Ph(CH₂)_n; R₁₀ = H, (substituted) alkyl, alkenyl, alkynyl, carbocyclyl(alkyl), etc.; R₁₁ = haloalkyl, (CH₂)_rCONR₈R₉, (substituted) alkyl, alkenyl, alkynyl, carbocyclyl, etc.; R₁₃ = H, (substituted) alkyl, Q(CH₂)_n, acyl, etc.], were prepared. Thus, 2-phenyl-1-(4-phenylpyridin-2-yl)ethanamine.2TFA (preparation given) in DMF at 0° was treated sequentially with Hunig's base, Boc-tranexamic acid, HOEt, and EDCI followed by warming to room temperature to give coupling product which was treated with CF₃CO₂H in CH₂Cl₂ to

give 4-aminomethylcyclohexanecarboxylic acid [2-phenyl-1-(4-phenylpyridin-2-yl)ethyl]amide bistrifluoroacetate. The compds. of Formula I are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. This invention also relates to pharmaceutical compns. comprising these compds. and methods of treating thromboembolic and/or inflammatory disorders using the same. Preferred I inhibited Factor XIa


with $K_i \leq 15 \mu\text{M}$.

IT 872458-93-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (claimed compound; preparation of pyridine carboxamides as serine protease inhibitors for treating thromboembolic and inflammatory disorders)

RN 872458-93-0 CAPLUS

CN Cyclohexanecarboxamide, 4-(aminomethyl)-N-[1-[4-(2-methoxyphenyl)-2-pyridinyl]-2-phenylethyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:1351066 CAPLUS
 DOCUMENT NUMBER: 144:88174
 TITLE: Preparation of pyridine carboxamides as serine protease inhibitors
 INVENTOR(S): Corte, James; Hangeland, Jon; Quan, Mimi; Smallheer, Joanne M.; Fang, Tianan
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 243 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005123680	A1	20051229	WO 2005-US20971	20050614 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 7429604	B2	20080930	US 2005-151627	20050613 <--
US 20060009455	A1	20060112		
AU 2005255029	A1	20051229	AU 2005-255029	20050614 <--
EP 1773775	A1	20070418	EP 2005-787697	20050614 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV,				

MK, YU

CN 101010299	A	20070801	CN 2005-80027485	20050614 <--
JP 2008502692	T	20080131	JP 2007-516646	20050614 <--
IN 2006DN07496	A	20070817	IN 2006-DN7496	20061212 <--
MX 2006PA14799	A	20070216	MX 2006-PA14799	20061215 <--
NO 2007000201	A	20070312	NO 2007-201	20070111 <--
KR 2007022867	A	20070227	KR 2007-700830	20070112 <--
PRIORITY APPLN. INFO.:			US 2004-579637P	P 20040615 <--
			US 2005-683838P	P 20050524
			US 2005-151627	A 20050613
			WO 2005-US20971	W 20050614

OTHER SOURCE(S): CASREACT 144:88174; MARPAT 144:88174
GI



AB Title compds. [I; A = (substituted) cycloalkyl, cycloalkenyl, Ph, naphthyl, heterocyclyl; X1-X4 = CR3, CR4, NR6, NO, CO; ≥1 of X1-X4 = CR3; X5 = N, NR6, NO; Z = CHR11, NR13; L = CONR10, CH2CONR10, CH2NR10CO, etc.; R3 = (CH2)rCONR8R9, Q(CH2)r, etc.; r = 0-4; Q = (substituted) Ph, heterocyclyl; R4 = H, O, F, Cl, Br, iodo, OCF3, CF3, cyano, NO2, CONR8R9, etc.; R6 = H, alkyl, haloalkyl, (substituted) Ph(CH2)r, etc.; R8 = H, (substituted) alkyl, Q(CH2)n; n = 0-4; R9 = H, (substituted) Ph(CH2)n; R10 = H, (substituted) alkyl, alkenyl, alkynyl, carbocyclyl(alkyl), etc.; R11 = haloalkyl, (CH2)rCONR8R9, (substituted) alkyl, alkenyl, alkynyl, carbocyclyl, etc.; R13 = H, (substituted) alkyl, Q(CH2)n, acyl, etc.], were prepared. Thus, 2-phenyl-1-(4-phenylpyridin-2-yl)ethanamine.2TFA (preparation given) in DMF at 0° was treated sequentially with Hunig's base, Boc-tranexamic acid, HOBT, and EDCI followed by warming to room temperature to give coupling product which was treated with CF3CO2H in CH2Cl2

to

give 4-aminomethylcyclohexanecarboxylic acid [2-phenyl-1-(4-phenylpyridin-2-yl)ethyl]amide bistrifluoroacetate.

Preferred I inhibited Factor XIa with Ki ≤15 μM.

IT 872458-93-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of pyridine carboxamides as serine protease inhibitors)

RN 872458-93-0 CAPLUS

CN Cyclohexanecarboxamide, 4-(aminomethyl)-N-[1-[4-(2-methoxyphenyl)-2-pyridinyl]-2-phenylethyl]-, trans- (CA INDEX NAME)


Relative stereochemistry.




REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1004708 CAPLUS
DOCUMENT NUMBER: 143:306182
TITLE: Preparation of 1-aminocyclopropane-1-carboxamide derivatives as bradykinin B1 antagonists
INVENTOR(S): Bock, Mark G.; Feng, Dong-Mei; Kuduk, Scott
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005085198	A2	20050915	WO 2005-US6230	20050225 <--
WO 2005085198	A3	20051124		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005219836	A1	20050915	AU 2005-219836	20050225 <--
CA 2557858	A1	20050915	CA 2005-2557858	20050225 <--
EP 1723143	A2	20061122	EP 2005-714101	20050225 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LV				
CN 1926136	A	20070307	CN 2005-80006734	20050225 <--
JP 2007526311	T	20070913	JP 2007-501866	20050225 <--
IN 2006DN05022	A	20070413	IN 2006-DN5022	20060831 <--
PRIORITY APPLN. INFO.:			US 2004-549379P	P 20040302 <--
			WO 2005-US6230	W 20050225
OTHER SOURCE(S):	CASREACT 143:306182; MARPAT 143:306182			
GI				



I



II

AB Title compds. I [wherein R_{1a}, R_{1b}, R_{1c} = H or F; R₂ = H or Cl; R₃ = Cl or F; R₄ = (un)substituted (cyclo)alkyl, aryl or heterocycle, or pharmaceutically acceptable salts thereof] were prepared as antagonists or inverse agonists of bradykinin receptors, especially as antagonists of bradykinin receptor B₁. For instance, II was synthesized by acylation of dihydrochloride salt of the corresponding cyclopropanamine with 5-methylisoxazole-3-carbonyl chloride in the presence of DIPEA. I exhibited affinity for the B₁ receptor with IC₅₀ values of < 5μM. Therefore, I and their pharmaceutical compns. (examples given) are useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B₁ pathway.

IT 864641-38-3P 864641-40-7P 864641-42-9P

864641-44-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of aminocyclopropanecarboxamide derivs. as bradykinin B₁ antagonists)

RN 864641-38-3 CAPLUS

CN 3-Isoxazolecarboxamide, N-[1-[[[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-5-methyl-

(CA INDEX NAME)


Absolute stereochemistry.



RN 864641-40-7 CAPLUS

CN 5-Isoxazolecarboxamide, N-[1-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]-3-methoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-42-9 CAPLUS

CN 2-Furancarboxamide, N-[1-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]-5-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 864641-44-1 CAPLUS

CN 2-Pyrazinecarboxamide, N-[1-[(1R)-1-[5-[3,5-dichloro-2-(2,2-

difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 864641-46-3P 864641-48-5P 864641-49-6P
864641-50-9P 864641-51-0P 864641-52-1P
864641-53-2P 864641-54-3P 864641-55-4P
864641-56-5P 864641-57-6P 864641-58-7P
864641-59-8P 864641-60-1P 864641-61-2P
864641-62-3P 864641-63-4P 864641-65-6P
864641-66-7P 864641-68-9P 864641-69-0P
864641-70-3P 864641-72-5P 864641-74-7P
864641-76-9P 864641-78-1P 864641-80-5P
864641-82-7P 864641-84-9P 864641-85-0P
864641-86-1P 864641-88-3P 864641-90-7P
864641-92-9P 864641-93-0P 864641-94-1P
864641-96-3P 864641-98-5P 864642-00-2P
864642-01-3P 864642-02-4P 864642-03-5P
864642-05-7P 864642-06-8P 864642-08-0P
864642-09-1P 864642-10-4P 864642-12-6P
864642-14-8P 864642-16-0P 864642-18-2P
864642-20-6P 864642-22-8P 864642-24-0P
864642-25-1P 864642-26-2P 864642-27-3P
864642-28-4P 864642-29-5P 864642-30-8P
864642-31-9P 864642-32-0P 864642-34-2P
864642-35-3P 864642-37-5P 864642-38-6P
864642-39-7P 864642-41-1P 864642-43-3P
864642-45-5P 864642-47-7P 864642-49-9P
864642-51-3P 864642-53-5P 864642-54-6P
864642-55-7P 864642-56-8P 864642-58-0P
864642-60-4P 864642-62-6P 864642-64-8P
864642-66-0P 864642-68-2P 864642-70-6P
864642-72-8P 864642-74-0P 864642-76-2P
864642-78-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminocyclopropanecarboxamide derivs. as bradykinin B1 antagonists)

RN 864641-46-3 CAPLUS

CN 5-Isoxazolecarboxamide, 3-chloro-N-[1-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-48-5 CAPLUS

CN Cyclopropanecarboxamide, N-[1-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]-2,2-difluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-49-6 CAPLUS

CN 4-Pyridazinecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 864641-50-9 CAPLUS

CN 4-Pyridazinecarboxamide, N-[1-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-

pyridinyl]ethyl]amino]carbonyl]cyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-51-0 CAPLUS

CN Cyclopropanecarboxamide, 1-(acetylamino)-N-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-52-1 CAPLUS

CN 5-Isoxazolecarboxamide, N-[1-[[[1R)-1-[5-[3,5-dichloro-2-(2,2,2-trifluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-3-methoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-53-2 CAPLUS

CN 5-Isoxazolecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-3-methoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-54-3 CAPLUS

CN 5-Isoxazolecarboxamide, 3-chloro-N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-55-4 CAPLUS

CN 5-Thiazolecarboxamide, 2-bromo-N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-56-5 CAPLUS

CN Cyclopropanecarboxamide, 1-[(2-cyanoacetyl)amino]-N-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-57-6 CAPLUS

CN 5-Thiazolecarboxamide, N-[1-[[[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-2-(methoxymethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-58-7 CAPLUS

CN 2-Pyrazinecarboxamide, 6-chloro-N-[1-[[[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-59-8 CAPLUS

CN 5-Thiazolecarboxamide, N-[1-[[[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-60-1 CAPLUS

CN 3-Isoxazolecarboxamide, N-[1-[[[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 864641-61-2 CAPLUS

CN 5-Thiazolecarboxamide, 2-chloro-N-[1-[[[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]- (CA INDEX NAME)

INDEX NAME)


Absolute stereochemistry.



RN 864641-62-3 CAPLUS

CN 5-Isoazolecarboxamide, N-[1-[[[(1R)-1-[3-chloro-5-(3,5-dichloro-2-ethoxyphenyl)-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-3-methoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-63-4 CAPLUS

CN 5-Oxazolecarboxamide, N-[1-[[[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-2-methoxy- (CA INDEX NAME)

Absolute stereochemistry.




RN 864641-65-6 CAPLUS

CN 5-Iothiazolecarboxamide, N-[1-[[[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-2-methoxy-

3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-3-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-66-7 CAPLUS

CN 5-Isoxazolecarboxamide, N-[1-[(1R)-1-[3-chloro-5-(3,5-dichloro-2-(2,2-difluoroethoxy)phenyl)-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-3-methoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-68-9 CAPLUS

CN 3-Isoxazolecarboxamide, N-[1-[(1R)-1-[3-chloro-5-(3,5-dichloro-2-ethoxyphenyl)-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-69-0 CAPLUS

CN 5-Isooxazolecarboxamide, N-[1-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-3-ethoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-70-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-72-5 CAPLUS


CN 5-Isooxazolecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-3-ethoxy- (CA INDEX NAME)

Absolute stereochemistry.




RN 864641-74-7 CAPLUS
CN 5-Oxazolecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-2,3-dihydro-2-oxo- (CA INDEX NAME)

Absolute stereochemistry.




RN 864641-76-9 CAPLUS
CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[3-chloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864641-78-1 CAPLUS
CN 2-Furancarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-80-5 CAPLUS

CN 2-Furancarboxamide, 5-bromo-N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-82-7 CAPLUS

CN 5-Thiazolecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-2-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 864641-84-9 CAPLUS

CN 2-Pyrazinecarboxamide, 6-chloro-N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]- (CA INDEX NAME)

INDEX NAME)


Absolute stereochemistry.



RN 864641-85-0 CAPLUS

CN 4-Oxazolecarboxamide, N-[1-[[[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]-5-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-86-1 CAPLUS

CN 3-Isoxazolecarboxamide, 5-cyclopropyl-N-[1-[[[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-88-3 CAPLUS

CN Cyclopropanecarboxamide, N-[{(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl}-1-(1-oxopropyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-90-7 CAPLUS

CN 1H-Pyrazole-4-carboxamide, N-[1-[[[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-1-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 864641-92-9 CAPLUS

CN 3-Isoxazolecarboxamide, N-[1-[[[(1R)-1-[5-[3,5-dichloro-2-(2,2-

difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-5-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-93-0 CAPLUS

CN 1,2,3-Thiadiazole-5-carboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-4-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-94-1 CAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]-1-[(2-(methylsulfonyl)acetyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-96-3 CAPLUS

CN 5-Isoxazolecarboxamide, N-[1-[[[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-3-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864641-98-5 CAPLUS

CN 3-Isoxazolecarboxamide, N-[1-[[[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-5-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-00-2 CAPLUS

CN 2-Furancarboxamide, N-[1-[[[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-01-3 CAPLUS

CN 2-Furancarboxamide, N-[1-[[[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-5-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-02-4 CAPLUS

CN 2-Pyrazinecarboxamide, N-[1-[[[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-6-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-03-5 CAPLUS

CN 3-Isoxazolecarboxamide, 5-cyclopropyl-N-[1-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-05-7 CAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-(3-chloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 864642-06-8 CAPLUS

CN 1,3,4-Oxadiazole-2-carboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-5-

methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-08-0 CAPLUS

CN 2-Pyrazinecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-09-1 CAPLUS


CN 5-Isoxazolecarboxamide, N-[1-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]-3-phenyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 864642-10-4 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[1-[[[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-5-oxo-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 864642-12-6 CAPLUS
CN 1H-Pyrazole-4-carboxamide, N-[1-[[[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-1-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 864642-14-8 CAPLUS
CN 3-Isoxazolecarboxamide, N-[1-[[[(1R)-1-[3-chloro-5-[3,5-dichloro-2-(2,2,2-trifluoroethoxy)phenyl]-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-16-0 CAPLUS

CN 1,2,5-Oxadiazole-3-carboxamide, N-[1-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]-4-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-18-2 CAPLUS

CN 5-Oxazolecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-20-6 CAPLUS

CN Cyclopropanecarboxamide, 1-(acetylamino)-N-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-22-8 CAPLUS

CN 5-Isothiazolecarboxamide, 3,4-dichloro-N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-24-0 CAPLUS

CN 1H-1,2,3-Triazole-4-carboxamide, N-[1-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]-1-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-25-1 CAPLUS

CN 5-Isoxazolecarboxamide, N-[1-[[[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-2,3-dihydro-3-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-26-2 CAPLUS

CN 3-Isoxazolecarboxamide, N-[1-[[[(1R)-1-[3-chloro-5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-5-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 864642-27-3 CAPLUS

CN 1H-Tetrazole-5-carboxamide, N-[1-[[[(1R)-1-[5-(3,5-dichloro-2-

ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-1-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-28-4 CAPLUS

CN Cyclopropanecarboxamide, N-[1-[(1R)-1-[5-[3,5-dichloro-2-(2,2,2-trifluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-2,2-difluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-29-5 CAPLUS

CN 1,2,3-Thiadiazole-4-carboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-30-8 CAPLUS

CN 3-Isoxazolecarboxamide, N-[1-[[[(1R)-1-[3-chloro-5-(3,5-dichloro-2-ethoxyphenyl)-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-5-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-31-9 CAPLUS

CN Benzamide, N-[1-[[[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-3-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-32-0 CAPLUS

CN Cyclopropanecarboxamide, 1-[(2-chloro-2,2-difluoroacetyl)amino]-N-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-34-2 CAPLUS

CN 3-Isoxazolecarboxamide, N-[1-[(1R)-1-[3-chloro-5-[3,5-dichloro-2-(2,2,2-trifluoroethoxy)phenyl]-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-5-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-35-3 CAPLUS


CN Cyclopropanecarboxamide, N-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]-1-[(1-oxobutyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 864642-37-5 CAPLUS
 CN Cyclopropanecarboxamide, N-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]-1-[(2-methyl-1-oxopropyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864642-38-6 CAPLUS
 CN 5-Thiazolecarboxamide, N-[1-[[[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-39-7 CAPLUS

CN 3-Isoxazolecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-5-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-41-1 CAPLUS

CN Benzamide, 3-chloro-N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-43-3 CAPLUS

CN 5-Isoxazolecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-2,3-dihydro-3-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-45-5 CAPLUS

CN 2H-Tetrazole-5-carboxamide, N-[1-[[[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-47-7 CAPLUS

CN 1H-1,2,3-Triazole-4-carboxamide, N-[1-[[[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-1-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 864642-49-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[1-[[[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-

pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-5-oxo-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-51-3 CAPLUS

CN 1H-Imidazole-5-carboxamide, N-[1-[[[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-1-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-53-5 CAPLUS

CN 2-Pyrazinecarboxamide, N-[1-[[[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-3-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-54-6 CAPLUS

CN 1*H*-Pyrazole-5-carboxamide, N-[1-[(1*R*)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-1-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-55-7 CAPLUS

CN 5-Thiazolecarboxamide, N-[1-[(1*R*)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-4-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 864642-56-8 CAPLUS

CN 2*H*-1,2,3-Triazole-4-carboxamide, N-[1-[(1*R*)-1-[5-(3,5-dichloro-2-

ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-58-0 CAPLUS

CN 4-Isothiazolecarboxamide, 3,5-dichloro-N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-60-4 CAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]-1-[(2,2-difluoroacetyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-62-6 CAPLUS

CN 4-Oxazolecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-64-8 CAPLUS

CN 3-Thiophenecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-66-0 CAPLUS

CN 3-Pyridazinecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-68-2 CAPLUS

CN 4-Thiazolecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]cyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-70-6 CAPLUS

CN 2-Thiazolecarboxamide, N-[1-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]cyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-72-8 CAPLUS

CN 4-Isoxazolecarboxamide, N-[1-[[[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-3-methyl-5-(trifluoromethyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 864642-74-0 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-[1-[[[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-1-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-76-2 CAPLUS

CN 2-Furancarboxamide, N-[1-[[[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-5-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-78-4 CAPLUS

CN 4H-1,2,4-Triazole-3-carboxamide, N-[1-[[[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-4-methyl- (CA INDEX NAME)

Absolute stereochemistry.




IT 864642-89-7P 864642-91-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aminocyclopropanecarboxamide derivs. as bradykinin B1 antagonists)

RN 864642-89-7 CAPLUS

CN Carbamic acid, [1-[[[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 864642-91-1 CAPLUS

CN Cyclopropanecarboxamide, 1-amino-N-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:612238 CAPLUS

DOCUMENT NUMBER: 143:133188

TITLE: Preparation of α-hydroxy carboxamides, particularly N-biphenylmethyl and N-phenylpyridin-2-ylmethyl amides, as bradykinin B1 antagonists or inverse agonists useful in the treatment of pain and inflammation

INVENTOR(S): Wood, Michael R.; Anthony, Neville J.; Bock, Mark G.; Kuduk, Scott D.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 51 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005063690	A1	20050714	WO 2004-US42691	20041217 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004309357	A1	20050714	AU 2004-309357	20041217 <--
CA 2550372	A1	20050714	CA 2004-2550372	20041217 <--
EP 1706372	A1	20061004	EP 2004-814829	20041217 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
CN 1898198	A	20070117	CN 2004-80038255	20041217 <--
BR 2004017928	A	20070417	BR 2004-17928	20041217 <--
JP 2007520472	T	20070726	JP 2006-547200	20041217 <--
IN 2006DN03156	A	20070824	IN 2006-DN3156	20060602 <--
MX 2006PA07203	A	20060818	MX 2006-PA7203	20060621 <--
KR 2006115753	A	20061109	KR 2006-712382	20060621 <--
NO 2006003394	A	20060912	NO 2006-3394	20060721 <--
PRIORITY APPLN. INFO.:			US 2003-531643P	P 20031222 <--
			US 2004-539637P	P 20040128 <--
			US 2004-624958P	P 20041104 <--
			WO 2004-US42691	W 20041217 <--

OTHER SOURCE(S): CASREACT 143:133188; MARPAT 143:133188
GI



AB Title compds. [I; Y = CH, N; R1 = (un)substituted Ph, 2,2-dioxo-2,1-benzisothiazolin-1-yl; R2 = H, (un)substituted alkyl, Ph, etc.; R3 = defined as R2; or R3 = OH; or R2CR3 = (un)substituted 3-7-membered carbocyclyl; R4, R5 = independently H, halo/alkyl; R7 = H, halo] were prepared as bradykinin B1 antagonists or inverse agonists useful in the treatment of pain and inflammation associated with the bradykinin B1 pathway. For example, coupling of 1-hydroxycyclopropanecarboxylic acid with Me 4'-(aminomethyl)biphenyl-2-carboxylate gave amide II. I have

affinity for the B1 receptor in a radioligand assay as demonstrated by results of less than 5 μ M [sic].

IT 858412-84-7P 858412-88-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of N-biphenylmethyl and N-phenylpyridin-2-ylmethyl α -hydroxycarboxamides as bradykinin B1 antagonists or inverse agonists useful in the treatment of pain and inflammation)

RN 858412-84-7 CAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]-1-hydroxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 858412-88-1 CAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]-1-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:71170 CAPLUS

DOCUMENT NUMBER: 142:176693

TITLE: Preparation of phenylpyridine derivatives as herbicides


INVENTOR(S): Takizawa, Eiji; Kumata, Shuji; Kiyokawa, Takahiro

PATENT ASSIGNEE(S): Nihon Nohyaku Co., Ltd., Japan

SOURCE: PCT Int. Appl., 67 pp.

CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005007627	A1	20050127	WO 2004-JP10560	20040716 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2005053902	A	20050303	JP 2004-211469	20040720 <--
PRIORITY APPLN. INFO.:			JP 2003-277112	A 20030718 <--
OTHER SOURCE(S):	MARPAT 142:176693			
GI				



AB The title compds. I [A1 represents N:(O)p; A2 represents (CR₃R₃)i; R₁ represents hydrogen, etc., and R₂ represents hydrogen, etc., provided that R₁ and R₂ in combination can form a 4- to 8-membered ring containing X, carbon, nitrogen, oxygen, or sulfur; R₃'s may be the same or different and each represents hydrogen, etc., provided that two R₃'s in combination can form a 3- to 6-membered ring containing carbon, nitrogen, oxygen, or sulfur; R₄'s may be the same or different and each represents halogeno, etc.; R₅'s may be the same or different and each represents halogeno, etc., provided that two adjacent R₅'s can be bonded to each other to form OCF₂₀, etc.; X represents CO, CS, or SO_q (wherein q is 1 or 2); i is an integer of 0 to 2; m is an integer of 0 to 3; n is an integer of 1 to 5; and p is 0 or 1] are prepared. Thus, N-[6-(3-trifluoromethoxyphenyl)-2-pyridyl]methylcyclopropanecarboxamide was prepared by reaction of 6-(3-trifluoromethoxyphenyl)-2-pyridylmethylamine with cyclopropanecarbonyl chloride in toluene containing triethylamine. 59 Compds. of this invention at 1000 g/ha gave ≥ 90% control of Lindernia pyxidaria.


IT 833456-18-1P 833456-86-3P
 RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of phenylpyridine derivs. as herbicides)
 RN 833456-18-1 CAPLUS

CN Cyclopropanecarboxamide, N-[6-[2-(trifluoromethoxy)phenyl]-2-pyridinyl]methyl]- (CA INDEX NAME)



RN 833456-86-3 CAPLUS

CN Cyclopropanecarboxamide, N-[4-methyl-6-[2-(trifluoromethoxy)phenyl]-2-pyridinyl]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 203 THERE ARE 203 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:203618 CAPLUS

DOCUMENT NUMBER: 140:253570

TITLE: Preparation of N-biaryl methylaminocycloalkanecarboxamide as bradykinin B1 antagonists

INVENTOR(S): Kuduk, Scott D.; Wood, Michael R.; Bock, Mark G.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004019868	A2	20040311	WO 2003-US26628	20030825 <--
WO 2004019868	A3	20040429		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,			

FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2495914	A1	20040311	CA 2003-2495914	20030825 <--
AU 2003265674	A1	20040319	AU 2003-265674	20030825 <--
BR 2003013239	A	20050614	BR 2003-13239	20030825 <--
EP 1545538	A2	20050629	EP 2003-791763	20030825 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1678320	A	20051005	CN 2003-820293	20030825 <--
JP 2005537323	T	20051208	JP 2004-532994	20030825 <--
US 20050288305	A1	20051229	US 2005-523911	20050208 <--
US 7163951	B2	20070116		
IN 2005CN00256	A	20070907	IN 2005-CN256	20050224 <--
MX 2005PA02245	A	20050608	MX 2005-PA2245	20050225 <--
NO 2005001539	A	20050525	NO 2005-1539	20050323 <--
PRIORITY APPLN. INFO.:			US 2002-406742P	P 20020829 <--
			WO 2003-US26628	W 20030825 <--

OTHER SOURCE(S): MARPAT 140:253570
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [Het = pyridyl, pyrimidinyl, N-oxide thereof; R1-2 = H, alkyl; R3a-3b = H, alkyl; R4a-4b = H, halo, alkyl, etc.; R5 = alkyl, cycloalkyl, alkynyl, alkenyl, etc.; R6a = alkyl, cycloalkyl, alkenyl, etc.; R6b-6c = H and not more than one of R6a-6c = heterocycle; R7a-7b = H, halo, CN, etc.; m = 0-3] are prepared. For instance, 1-[(pyrimidin-5-yl)carbonyl]amino)cyclobutanecarboxylic acid (preparation given) is coupled to Me 2-[2-(aminomethyl)pyrimidin-5-yl]-6-fluorobenzoate (preparation given; DMF, HOBT, EDCI, Et3N) to give II. Compds. of the invention have affinity for the bradykinin B1 receptor at less than 5 μ M. I are useful for the treatment of pain and inflammation.


IT 669066-85-7P, 1-[(Trifluoromethyl)carbonyl]amino]-1-[[[5-[2-[2-fluoro-2-(fluoromethyl)ethoxy]-3-(chloro)-5-(chlorophenyl)-3-chloropyridin-2-yl]methyl]amino]carbonyl]cyclopropane 669066-86-8P, 1-[(Trifluoromethyl)carbonyl]amino]-1-[[[5-[2-[2-fluoro-2-(fluoromethyl)ethoxy]-3-(chloro)-5-(chlorophenyl)-3-pyridin-2-yl]methyl]amino]carbonyl]cyclopropane 669066-87-9P, 1-[(Trifluoromethyl)carbonyl]amino]-1-[[[5-[2-(carbomethoxy)oxy]-3-(fluoro)phenyl]-3-fluoropyridin-2-yl]methyl]amino]carbonyl]cyclopropane 669067-11-2P, (R)-1-[(Trifluoromethyl)carbonyl]amino]-1-[[1-[5-[2-(difluoromethoxy)-3-(fluoro)phenyl]-3-fluoropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-15-6P, (R)-1-[(Trifluoromethyl)carbonyl]amino]-1-[[1-[5-[2-(2,2,2-trifluoroethoxy)-3-(fluoro)phenyl]-3-fluoropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-17-8P 669067-18-9P 669067-19-0P, (R)-1-[(Trifluoromethyl)carbonyl]amino]-1-[[1-[5-[2-(2,2-difluoroethoxy)-3-(fluoro)phenyl]-3-fluoropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-39-4P, (R)-1-[(Trifluoromethyl)carbonyl]amino]-1-[[1-[5-[2-(ethoxy)-3-(fluoro)-5-(chlorophenyl)-3-fluoropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-40-7P, (R)-1-[(Trifluoromethyl)carbonyl]amino]-1-[[1-[5-[2-(2-fluoroethoxy)-3-(fluoro)-5-(chlorophenyl)-3-fluoropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-42-9P, (R)-1-[(Trifluoromethyl)carbonyl]amino]-1-[[1-[5-[2-(ethoxy)-3-(fluoro)-5-(chlorophenyl)-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-43-0P 669067-44-1P, (R)-1-[(1,2,5-Thiadiazol-3-yl)carbonyl]amino]-1-[[1-[5-[2-(ethoxy)-3-

(fluoro)-5-(chloro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-46-3P,
(R)-1-[[[Trifluoromethyl]carbonyl]amino]-1-[[[1-[5-[2-(2,2,2-trifluoroethoxy)-3-(fluoro)-5-(chloro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-53-2P,
(R)-1-[[[Trifluoromethyl]carbonyl]amino]-1-[[[1-[5-[2-(2,2-difluoroethoxy)-3-(chloro)-5-(fluoro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-54-3P,
(R)-1-[[[Trifluoromethyl]carbonyl]amino]-1-[[[1-[5-[2-(ethoxy)-3-(chloro)-5-(fluoro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-56-5P, (R)-1-[[[Isoxazol-5-yl]carbonyl]amino]-1-[[[1-[2-(2,2,2-trifluoroethoxy)-3-(fluoro)-5-(chloro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-57-6P
669067-58-7P, (R)-1-[[[Trifluoromethyl]carbonyl]amino]-1-[[[1-[5-[2-(ethoxy)-3-(fluoro)-5-(fluoro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-59-8P,
(R)-1-[[[Trifluoromethyl]carbonyl]amino]-1-[[[1-[5-[2-(2,2-difluoroethoxy)-3-(fluoro)-5-(fluoro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-60-1P,
(R)-1-[[[Trifluoromethyl]carbonyl]amino]-1-[[[1-[5-[2-(2,2,2-trifluoroethoxy)-3-(chloro)-5-(fluoro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-62-3P,
(R)-1-[[[Isoxazol-5-yl]carbonyl]amino]-1-[[[1-[5-[2-(2,2-difluoroethoxy)-3-(fluoro)-5-(chloro)phenyl]pyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-64-5P, (R)-1-[[[Trifluoromethyl]carbonyl]amino]-1-[[[1-[5-[2-(ethoxy)-3-(chloro)-5-(chloro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-65-6P,
(R)-1-[[[Trifluoromethyl]carbonyl]amino]-1-[[[1-[5-[2-(2,2-difluoroethoxy)-3-(chloro)-5-(chloro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-66-7P,
(R)-1-[[[Isoxazol-5-yl]carbonyl]amino]-1-[[[1-[5-[2-(2,2-difluoroethoxy)-3-(chloro)-5-(fluoro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-67-8P,
(R)-1-[[[Isoxazol-5-yl]carbonyl]amino]-1-[[[1-[5-[2-(ethoxy)-3-(chloro)-5-(fluoro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-68-9P, (R)-1-[[[Trifluoromethyl]carbonyl]amino]-1-[[[1-[5-[2-(2,2,2-trifluoroethoxy)-3-(chloro)-5-(chloro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-70-3P,
(R)-1-[[[Isoxazol-5-yl]carbonyl]amino]-1-[[[1-[5-[2-(2,2,2-trifluoroethoxy)-3-(chloro)-5-(fluoro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-71-4P,
(R)-1-[[[Trifluoromethyl]carbonyl]amino]-1-[[[1-[5-[2-(2,2-difluoroethoxy)-3-(fluoro)-5-(chloro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-72-5P,
(R)-1-[[[Trifluoromethyl]carbonyl]amino]-1-[[[1-[5-[2-(cyclopropyl)oxy]-3-(fluoro)-5-(fluoro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-73-6P,
(R)-1-[[[Isoxazol-3-yl]carbonyl]amino]-1-[[[1-[5-[2-(2,2-difluoroethoxy)-3-(fluoro)-5-(chloro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-75-8P,
(R)-1-[[[Isoxazol-5-yl]carbonyl]amino]-1-[[[1-[5-[2-(ethoxy)-3-(chloro)-5-(chloro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-76-9P, (R)-1-[[[Isoxazol-5-yl]carbonyl]amino]-1-[[[1-[5-[2-(2,2-difluoroethoxy)-3-(chloro)-5-(chloro)phenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane 669067-77-0P,
(R)-1-[[[Isoxazol-5-yl]carbonyl]amino]-1-[[[1-[5-[2-(2,2,2-trifluoroethoxy)-3-(chloro)-5-chlorophenyl]-3-chloropyridin-2-yl]ethyl]amino]carbonyl]cyclopropane


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-biaryl methylaminocycloalkanecarboxamide as bradykinin B1


antagonists)
 RN 669066-85-7 CAPLUS
 CN Cyclopropanecarboxamide, N-[3-chloro-5-[3,5-dichloro-2-(2,3-difluoropropoxy)phenyl]-2-pyridinyl]methyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)



RN 669066-86-8 CAPLUS
 CN Cyclopropanecarboxamide, N-[5-[3,5-dichloro-2-(2,3-difluoropropoxy)phenyl]-2-pyridinyl]methyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)




RN 669066-87-9 CAPLUS
 CN Carbonic acid, 2-fluoro-6-[5-fluoro-6-[[[[1-[(trifluoroacetyl)amino]cyclopropyl]carbonyl]amino]methyl]-3-pyridinyl]phenyl methyl ester (9CI) (CA INDEX NAME)



RN 669067-11-2 CAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[2-(difluoromethoxy)-3-fluorophenyl]-3-fluoro-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 669067-15-6 CAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-fluoro-5-[3-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 669067-17-8 CAPLUS


CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[2-(2,3-difluoropropoxy)-3-fluorophenyl]-3-fluoro-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 669067-18-9 CAPLUS
CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[2-(2,3-difluoropropoxy)-3-fluorophenyl]-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 669067-19-0 CAPLUS
CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[2-(2,2-difluoroethoxy)-3-fluorophenyl]-3-fluoro-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 669067-39-4 CAPLUS
CN Cyclopropanecarboxamide, N-[(1R)-1-[5-(5-chloro-2-ethoxy-3-fluorophenyl)-3-fluoro-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 669067-40-7 CAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[5-[5-chloro-3-fluoro-2-(2-fluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 669067-42-9 CAPLUS


CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-(5-chloro-2-ethoxy-3-fluorophenyl)-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 669067-43-0 CAPLUS
CN 5-Isoxazolecarboxamide, N-[1-[(1R)-1-[3-chloro-5-(5-chloro-2-ethoxy-3-fluorophenyl)-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 669067-44-1 CAPLUS
CN 1,2,5-Thiadiazole-3-carboxamide, N-[1-[(1R)-1-[3-chloro-5-(5-chloro-2-ethoxy-3-fluorophenyl)-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 669067-46-3 CAPLUS
CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[5-chloro-3-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 669067-53-2 CAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[3-chloro-2-(2,2-difluoroethoxy)-5-fluorophenyl]-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 669067-54-3 CAPLUS


CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-(3-chloro-2-ethoxy-5-fluorophenyl)-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 669067-56-5 CAPLUS
CN 5-Isoxazolecarboxamide, N-[1-[(1R)-1-[3-chloro-5-[5-chloro-3-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]-2-pyridinyl]ethyl]amino]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 669067-57-6 CAPLUS
CN Cyclopropanecarboxamide, N-[1-[(1R)-1-[3-chloro-5-[5-chloro-3-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]-2-pyridinyl]ethyl]amino]carbonyl]-2,2-difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 669067-58-7 CAPLUS
CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-(2-ethoxy-3,5-difluorophenyl)-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 669067-59-8 CAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[2-(2,2-difluoroethoxy)-3,5-difluorophenyl]-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 669067-60-1 CAPLUS


CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[3-chloro-5-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 669067-62-3 CAPLUS
CN 5-Isoxazolecarboxamide, N-[1-[(1R)-1-[5-[5-chloro-2-(2,2-difluoroethoxy)-3-fluorophenyl]-2-pyridinyl]ethyl]amino]carbonylcyclopropyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 669067-64-5 CAPLUS
CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-(3,5-dichloro-2-ethoxyphenyl)-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 669067-65-6 CAPLUS
CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 669067-66-7 CAPLUS

CN 5-Isoxazolecarboxamide, N-[1-[(1R)-1-[3-chloro-5-[3-chloro-2-(2,2-difluoroethoxy)-5-fluorophenyl]-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 669067-67-8 CAPLUS

CN 5-Isoxazolecarboxamide, N-[1-[(1R)-1-[3-chloro-5-(3-chloro-2-ethoxy-5-fluorophenyl)-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 669067-68-9 CAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[3,5-dichloro-2-(2,2,2-trifluoroethoxy)phenyl]-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 669067-70-3 CAPLUS

CN 5-Isoxazolecarboxamide, N-[1-[(1R)-1-[3-chloro-5-[3-chloro-5-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]-2-pyridinyl]ethyl]amino]cyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 669067-71-4 CAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[5-chloro-2-(2,2-difluoroethoxy)-3-fluorophenyl]-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 669067-72-5 CAPLUS

CN Cyclopropanecarboxamide, N-[(1R)-1-[3-chloro-5-[2-(cyclopropyl)oxy]-3,5-difluorophenyl]-2-pyridinyl]ethyl]-1-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 669067-73-6 CAPLUS

CN 3-Isoxazolecarboxamide, N-[1-[[[[(1R)-1-[3-chloro-5-[5-chloro-2-(2,2-difluoroethoxy)-3-fluorophenyl]-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 669067-75-8 CAPLUS

CN 5-Isoazolecarboxamide, N-[1-[[[(1R)-1-[3-chloro-5-(3,5-dichloro-2-ethoxyphenyl)-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 669067-76-9 CAPLUS

CN 5-Isoazolecarboxamide, N-[1-[[[(1R)-1-[3-chloro-5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 669067-77-0 CAPLUS

CN 5-Isoazolecarboxamide, N-[1-[[[(1R)-1-[3-chloro-5-[3,5-dichloro-2-(2,2,2-trifluoroethoxy)phenyl]-2-pyridinyl]ethyl]amino]carbonyl]cyclopropyl]- (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:971837 CAPLUS
 DOCUMENT NUMBER: 140:27621
 TITLE: Preparation of 1,2-diamido cycloalkyl sodium channel blockers
 INVENTOR(S): Fisher, Michael H.; Li, Chunshi; Liang, Jun; Meinke, Peter T.; Ok, Dong; Parsons, William H.; Shao, Pengcheng Patrick; Tyagarajan, Sriram
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA
 SOURCE: PCT Int. Appl., 133 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003101381	A2	20031211	WO 2003-US16335	20030523 <--
WO 2003101381	A3	20040212		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003237224	A1	20031219	AU 2003-237224	20030523 <--
PRIORITY APPLN. INFO.:			US 2002-383832P	P 20020529 <--
			WO 2003-US16335	W 20030523 <--

OTHER SOURCE(S): MARPAT 140:27621
 GI



AB The patent relates to the preparation of 1,2-diamido cycloalkyl compds. I ($X = \text{Ph, pyridyl, thienyl, etc.}$; $R1 = \text{H, C1-6 alkyl}$; $R2 = \text{C0-6 alkyl-Ph, C1-6 alkylthienyl, C1-6 alkylthiazolyl, etc.}$; $R1R2 = 5$ or 6 membered ring; $E = \text{C1-6 alkyl}$; $R3 = \text{C0-6 alkyl}$; $A = \text{CnH2n}$; $B = \text{CmH2m}$; $n, m = 0-3$; $n + m = 1-3$; $R4, R5 = \text{C0-6 alkyl, OH, halo, etc.}$). The 1,2-diamido cycloalkyl compds. are useful as: sodium channel blockers; pharmaceutical compns. that include an effective amount of the aryl-link-aryl thiazolidindione and aryl-link-aryl oxazolidinedione compds. and a pharmaceutically acceptable carrier; and a method of treatment of acute pain, chronic pain, visceral pain, inflammatory pain, or neuropathic pain, as well as irritable bowel syndrome, Crohn's disease, epilepsy, partial and generalized tonic seizures, multiple sclerosis, bipolar disease, and tachyarrhythmias by the administration of an effective amount of aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compds., either alone, or in combination with one or more therapeutically active compds. Thus, trans-1-(RS)-[4-(2-aminosulfonylphenyl)]benzylaminocarbonyl-2-(SR)-benzylaminocarbonylcyclopentane was prepared by reacting a mixture comprising 1-(RS)-[4-(2-aminosulfonylphenyl)]benzylaminocarbonyl-2-(SR)-carboxycyclopentane, N-hydroxybenzotriazole, diisopropylethylamine, benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate, and benzylamine wherein 1-(RS)-[4-(2-aminosulfonylphenyl)]benzylaminocarbonyl-2-(SR)-carboxycyclopentane was prepared from the reaction of trans-DL-cyclopentane dicarboxylic acid and 4-(2-aminosulfonylphenyl)benzylamine.

IT 632338-84-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1,2-diamido cycloalkyl sodium channel blockers)

RN 632338-84-2 CAPLUS

CN 1,2-Cyclopentanedicarboxamide, N1-methyl-N2-[[4-(trifluoromethoxy)phenyl]methyl]-N1-[[5-[2-(trifluoromethoxy)phenyl]-2-pyridinyl]methyl]-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



=> fil stnguide		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	41.23	220.26
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-5.60	-5.60

FILE 'STNGUIDE' ENTERED AT 13:30:10 ON 24 DEC 2008
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
 LAST RELOADED: Dec 19, 2008 (20081219/UP).

=> logoff		
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF		
LOGOFF? (Y)/N/HOLD:y		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.30	220.56
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-5.60

STN INTERNATIONAL LOGOFF AT 13:33:00 ON 24 DEC 2008